Common Rule and FDA Regulation Comparison David Forster Jeff Cooper Gary Chadwick.

Slides:

Advertisements

Similar presentations

1 The HIPAA Privacy Rule and Research This presentation will probably involve audience discussion, which will create action items. Use PowerPoint to keep.

Advertisements

THE UW HEALTH SCIENCES IRB S OVERVIEW PRACTICAL REGULATORY ISSUES IN HUMAN SUBJECTS RESEARCH.

Subcommittee on Harmonization Mark Barnes David Forster.

SUBPART D PRESENTATION Inaugural meeting of the Pediatric Ethics Subcommittee (PES) of the Pediatric Advisory Committee (PAC); part of the inaugural meeting.

1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.

Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.

1 © Huron Consulting Group Inc. All rights reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,

1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.

IRB 101: Informed Consent Columbia University Medical Center IRB September 22, 2005.

Mark Barnes David Forster October 19, 2010 SUBCOMMITTEE ON HARMONIZATION (SOH) UPDATE.

Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.

IRB-Investigator/ Research Coordinator Mtg. “What You Can Do to Facilitate an Efficient IRB Review” January 13, 2004 George Gasparis.

CUMC IRB Investigator Meeting November 9, 2004 Research Use of Stored Data and Tissues.

Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.

Renewing An Approved Protocol: IRB Review Process

HRPP Policies & Forms Created/Revised for AAHRPP.

Is this Research? Exempt? Expedited?

Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)

International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.

Primary Care and Community Outreach Research VCOM Institutional Review Board Jim Mahaney, PhD Associate Dean for Biomedical Affairs, Virginia Campus Past.

IRB Board Education Session 6 How Consent Regulations are Implemented in INSPIR Mary Banks Director, Office of the IRB June -July 2005.

Deciphering the Continuing Review Form Research Compliance Administration Training Presentation Wednesday, August 15, 2007 Presenter:Heather Kemp, MBA.

Mark Barnes David Forster July 21, 2010 Subcommittee on Harmonization (SOH) Update.

Planned Emergency Research Exception from Informed Consent Requirements September 2007.

HIPAA and Research Basics for IRB Tim Atkinson Director, Research and Sponsored Programs Director, Institutional Review Board Research Privacy Officer.

The Secretary’s Advisory Committee on Human Research Protections (SACHRP): Recommendations Regarding the Newborn Screening Reauthorization Act of 2014.

Privacy and Confidentiality. Definitions n Privacy - having control over the extent, timing, and circumstances of sharing oneself (physically, behaviorally,

IRB BASICS: Issues in Ethics and Human Subject Protections Prepared by Ed Merrill Department of Psychology November 12, 2009.

Human Subjects Research at ASU An Overview. Overview Definitions Historical Framework Federal Guidelines Human Subjects Research at ASU.

Status of SACHRP Recommendations July 2003-October 2008 Meeting of the Secretary’s Advisory Committee on Human Research Protections October 27, 2008 Michael.

Institutional Review Board Issues for Classroom Research Sharon McWhorter IRB Administrator, The University of Akron (With assistance from Phil Allen,

OHRP Guidance and Policy Development Process Secretary’s Advisory Committee on Human Research Protections Meeting October 27, 2008 Irene Stith-Coleman,

Welcome New IRB Members! Today we will discuss: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.

Determinations of Research, Human Subjects Research, Exemptions, and Expedited Review Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for.

Continuing Review Presented by: Karen Jeans, PhD, CCRN, CIP Program Analyst, COACH.

TUN IRB: The Basics February 26, IRB Function Review human-subject research Ensure the rights & welfare of human subjects are adequately protected.

Challenges of 21st Century Clinical Research from an Independent IRB’s View Chesapeake Research Review, Inc. Paul Goebel, CIP Vice President Matthew Whalen,

Case Studies: Puzzles in Human Research Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst, Program for Research Integrity Development and Education.

Regulatory requirements: children, assent, and consent waivers and waiver of documentation Bob Craig, 2007.

1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.

Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.

Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.

OHRP’s Compliance Oversight Procedures

Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.

Non-compliance with Human Subjects Research Regulations J. Bruce Smith, MD, CIP November 2014 Continuing Education for IRB Members.

Medical Research in Times of Bioterrorism - OHRP’s Perspective Michael A. Carome, M.D. Associate Director for Regulatory Affairs Office for Human Research.

Legal Responsibilities for Studies Conducted or Supported by HHS Michael A. Carome, M.D. Associate Director for Regulatory Affairs Office for Human Research.

Human Research Protection Program 101 March 20, 2007 Cincinnati, OH.

THE INSTITUTIONAL REVIEW BOARD. WHAT IS AN IRB? An IRB is committee set up by an institution to review, approve, and regulate research conducted under.

Children in Research: They’re Not Just Small Adults

Overview - Introduction

Updates to Expedited Review Procedures

Updates to Expedited Review Procedures

Overview - Introduction

Overview - Introduction

To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.

To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.

The HIPAA Privacy Rule and Research

Updates to Expedited Review Procedures

Jeffrey M. Cohen, Ph.D. Associate Dean,

Secondary Research with Identifiable Information and Biospecimens

Expedited Status Update January 14, 2019

An Introduction to Regulatory Changes to Human Subjects Research

To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.

Overview of Changes to Human Subjects Research Regulations

What are the Major Changes to the IRB under the Final Common Rule?

Additional Protections for Children Involved as Subjects in Research

Event Reporting in Human Subjects Research

Research with Human Subjects

Presentation transcript:

Common Rule and FDA Regulation Comparison David Forster Jeff Cooper Gary Chadwick

Outline Genesis of Panel Other topics considered Topics for today’s panel

Genesis of Panel SACHRP Charter: The Committee shall advise, consult with, and make recommendations on matters pertaining to the continuance and improvement of functions within the authority of the Department of Health and Human Services (HHS) directed toward protections for human subjects in research.

Genesis of Panel In addition, the Committee shall be responsible for reviewing selected ongoing work and planned activities of the Office of Human Research Protections (OHRP) and other offices/agencies within HHS responsible for human subjects protection.

Genesis of Panel DeGette Bill, “Protection for Participants in Research Act of 2009.” If passed, requires the Secretary of HHS to make a comparison of the Common Rule and FDA regulations Parts 50 and 56.

Possible Topics HHS definition of “research” compared to FDA definition of “clinical investigation.” HHS definition of “human subject” compared to FDA definition of “human subject.” HHS exemption categories compared to FDA exemption categories. HHS waiver of consent regulations compared to FDA waiver of consent regulations.

Possible Topics HHS waiver of documentation of consent regulations compared to FDA waiver of document of consent regulations. OHRP guidance on enrollment of Non-English speaking subjects compared to FDA guidance. OHRP guidance on establishing the anniversary date for IRB continuing review and FDA lacuna regarding this issue. FDA guidance on recruitment for research compared to OHRP guidance.

Possible Topics OHRP guidance on screening medical records prior to consent compared to FDA guidance.

Topics for this panel Is a planned protocol deviation for a single subject a change in research that needs prior IRB review? Definition of “minor changes in previously approved research” that qualify for expedited review.

I. Protocol Deviations Regarding one-time planned variations (OTPVs), SACHRP recommends that: 1. FDA and OHRP issue joint or consistent guidance; 2. FDA and OHRP do not consider OTPVs to be changes in approved research automatically requiring IRB review;

Protocol Deviations 3. FDA and OHRP require that OTPVs not be allowed unless the criteria and process for allowing OTPVs are described in the IRB-approved protocol.

II. Minor Changes Regarding the definition of "minor changes in previously approved research during the period (of one year or less) for which approval is authorized," SACHRP recommends that: 1. FDA and OHRP issue joint or consistent guidance;

Minor Changes 2. the definition of a minor change in research is; "A change that does not increase risk and does not materially change the risk/benefit ratio.”